Molecular-targeted therapy with BRAF and MEK inhibitors for PCP with BRAF mutation may achieve the goal of reducing tumor volume, thus becoming a neoteric treatment for PCP (Brastianos et al., 2014, 2016; Roque and Odia, 2017; Juratli et al., 2019). This evidence concerns the gene MAP2K7 and neoplasm.